Antibiotics

Abstract

As record heat interrupts work, overloads hospitals, and claims thousands of lives around the world, international experts are calling for climate change to be officially recognized as a global health emergency, in The Lancet's 2026 Countdown on Health and Climate Change. The rate of increase in many climate-related health threats is accelerating, while heat deaths linked to climate change have reached a record-high, and the economic toll is battering vulnerable sectors and communities the hardest," says climate health researcher Marina Romanello, executive director of The Lancet Countdown. They say the World Health Organization and United Nations must declare climate change a global health emergency, coordinate governments to put human health at the center of climate decisions, and increase grant-based funding to finance climate and health initiatives. "Ten years ago, we proposed that responding to climate change could offer the greatest health opportunity of the 21st century through adaptation efforts and rapid progress in phasing down fossil fuels and other emission sources", says global health expert and The Lancet Countdown co-chair Anthony Costello."

Abstract

Andelen varierade ganska mycket mellan flygplatserna, på Arlanda hade 23 procent av de kontrollerade resenärerna antibiotika med sig, att jämföra med 10 procent på både Landvetter och Gardermoen. Av de som anlände från EU- och EES-länder hade bara 3 procent antibiotika med sig, jämfört med 27 procent bland resenärer från Asien. – Man kan i alla fall inte säga att det här inte är ett problem, utan det är något man behöver titta närmare på, säger Anna Moberg, universitetslektor vid Linköpings universitet och ansvarig för studien, i ett pressmeddelande. Resultaten kan därför egentligen inte användas för att uppskatta hur stor andel av alla flygresenärer som för in antibiotika.

Abstract

Jeg er helt sikker på, at et stærkere netværk på tværs af Europa vil gavne både danske farmaceuter og vores kolleger i andre europæiske lande, siger Susie Stærk Ekstrand. Ni europæiske farmaceutforeninger har stiftet EPA, men organisationen håber, at det nye samarbejde kan være med til at sikre, at der bliver etableret endnu flere medlemsorganisationer for farmaceuter og life science-professionelle i Europa. Mark Koziol, der er formand for britiske The Pharmacists' Defence Association (PDA), bliver EPA-formand, mens Greta Torbergsen, der er generalsekretær for Norges Farmaceutiske Forening, og Piotr Merks, der er generalsekretær for den polske farmaceutforening ZZPF, bliver næstformænd. Vi er specialister i life science, og vi deltager aktivt i den politiske debat, så vi er med til at sikre en stærk life science-branche i Danmark."

Abstract

A 2025 graduate of Harvard's joint MS/MBA biotechnology program, he previously worked at Prime Medicine, a Cambridge-based gene-editing company developing therapies based on prime editing, and at Casdin Capital, a New York life-sciences investment firm focused on biotech and genomics. Mithril's team designed and oversaw the experiments, contract laboratories produced the antibodies, measured their binding, ran cell-based assays and conducted the mouse studies. Researchers assigned treatment by litter without randomization and tested the antibody group 126 to 161 days after the control group, with a colony relocation in between. When a team member overruled its recommendation to measure how quickly all 113 bound to and detached from their targets, Claude revised the plan and related drafts to cover 89 within four minutes.

Abstract

Developing a drug involves many varied tasks: doing early research to identify a target for a drug and the right type of drug to engage it, designing a molecule with the right properties, optimizing it to be manufactured reliably at scale, drafting the regulatory filings needed to run clinical trials, designing and administering those trials, and much more. First, it lets us better understand the strengths and limitations of our models in relation to a much wider range of drug development tasks (we've already prioritized specific improvements to our models based on what we've learned so far). One design was about 70% shorter than the standard version, and in lab tests it was more effective: it allowed immune cells to make roughly 10 times as many receptors (the proteins they use to spot cancer cells), it killed tumor cells more efficiently, and the immune cells remained active for longer. BigHat's scientists and an Anthropic researcher worked with Claude to improve these three properties in two leads, both antibody fragments that could become parts of future drugs: one designed to target cancer cells, and one designed to keep a drug in the body longer.